The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).
 
Marla Lipsyc-Sharf
No Relationships to Disclose
 
Elza De Bruin
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Katheryn Santos
No Relationships to Disclose
 
Robert McEwen
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Daniel Stetson
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
Patents, Royalties, Other Intellectual Property - I have a patent pending for AstraZeneca
 
Ashka Patel
No Relationships to Disclose
 
Gregory J. Kirkner
No Relationships to Disclose
 
Melissa E. Hughes
No Relationships to Disclose
 
Sara M. Tolaney
Consulting or Advisory Role - 4D Pharma; AstraZeneca; Athenex; BeyondSpring Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; Certara Inc; Chugai Pharma; CytomX Therapeutics; Daiichi Sankyo; Eisai; Ellipses Pharma; G1 Therapeutics; Genentech; Immunomedics/Gilead; Infinity Pharmaceuticals; Kyowa Hakko Kirin; Lilly; Merck; Mersana; NanoString Technologies; Nektar; Novartis; Odonate Therapeutics; OncoPep; OncoSec; OncXerna Therapeutics; Paxman; Pfizer; Puma Biotechnology; Reveal Genomics; Samsung Bioepis; Sanofi; Seagen; Zentalis; Zymeworks
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cyclacel (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Lilly (Inst); Merck (Inst); NanoString Technologies (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst)
 
Ian E. Krop
Employment - Freeline Therapeutics (I); PureTech (I)
Leadership - Freeline Therapeutics (I); PureTech (I)
Stock and Other Ownership Interests - Freeline Therapeutics (I); PureTech (I)
Honoraria - AstraZeneca; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Genentech/Roche; Macrogenics; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
 
Charlene Knape
Employment - Inivata
 
Ute Feger
Employment - Inivata
 
Giovanni Marsico
Employment - Inivata
 
Karen Howarth
Employment - Inivata
Stock and Other Ownership Interests - Inivata; NeoGenomics Laboratories
Research Funding - Inivata
Patents, Royalties, Other Intellectual Property - Patent pending
 
Eric P. Winer
Honoraria - Genentech/Roche; Genomic Health
Consulting or Advisory Role - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; Jounce Therapeutics; Leap Therapeutics
Research Funding - Genentech (Inst)
Other Relationship - InfiniteMD
 
Nancy U. Lin
Stock and Other Ownership Interests - Artera
Consulting or Advisory Role - Affinia Therapeutics; Aleta Biotherapeutics; Artera; AstraZeneca; Daiichi Sankyo; Denali Therapeutics; Olema Pharmaceuticals; Pfizer; Prelude Therapeutics; Puma Biotechnology; Seagen; Voyager Therapeutics
Research Funding - Genentech (Inst); Merck (Inst); Olema Pharmaceuticals (Inst); Pfizer (Inst); Seagen (Inst); Zion Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for chapter in Up-to-Date regarding management of breast cancer brain metastases; Royalties, Jones & Bartlett
 
Heather Anne Parsons
Research Funding - Puma Biotechnology (Inst)